Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia/Lymphoma and Non-Hodgkin Lymphoma With Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor

NCT01865617 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT01865617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01865617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia/Lymphoma and Non-Hodgkin Lymphoma With Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 1/2
Overall status
Completed
Start date
May 22, 2013
Completion date
March 26, 2021
Enrollment
204 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cd19-positive neoplastic cells present, recurrent adult acute lymphoblastic leukemia, recurrent chronic lymphocytic leukemia, recurrent diffuse large b-cell lymphoma, recurrent mantle cell lymphoma, recurrent non-hodgkin lymphoma, recurrent small lymphocytic lymphoma, refractory acute lymphoblastic leukemia, refractory chronic lymphocytic leukemia, refractory diffuse large b-cell lymphoma, refractory mantle cell lymphoma, refractory non-hodgkin lymphoma, refractory small lymphocytic lymphoma